K. Anasti

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies

This study uses molecular dynamics simulations to design HIV-1 immunogens that select for specific mutations in broadly neutralizing antibodies.

Class-specific sensing of HIV-1 antigens by the B cell antigen receptor depends on the CH1 domain

This study shows that IgM and IgG1 BCRs differ in antigen sensing based on valency, with IgM preferring monovalent and IgG1 preferring polyvalent antigens, and identifies the CH1 domain as responsible for this difference.

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

This study shows non-neutralizing SARS-CoV-2 antibodies protect mice from severe disease via Fc-mediated effector functions, reducing viral load and lung damage.

Vaccine induction of CD4-mimicking broadly neutralizing antibody precursors in macaques

This study shows that vaccinating macaques with a CD4bs-targeting immunogen elicits neutralizing bnAb precursors with structural features of CD4-mimicking antibodies.

Structural basis for breadth development in a HIV-1 neutralizing antibody

This paper determines structures of HIV-1 antibodies at different stages of maturation to understand how neutralization breadth develops through affinity optimization.

B cells discriminate HIV-1 Envelope protein affinities by sensing antigen binding association rates

This study investigates how B cells distinguish HIV-1 Env proteins based on binding kinetics rather than equilibrium dissociation constants.

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

A broadly neutralizing antibody protects against multiple SARS-CoV and SARS-CoV-2 variants in mice by targeting a conserved epitope in the receptor-binding domain.